15.04.2020 M1 Kliniken AG  DE000A0STSQ8

DGAP-News: M1 Kliniken AG publishes preliminary figures for fiscal year 2019: Net income increases by almost 50 %


 

DGAP-News: M1 Kliniken AG / Key word(s): Preliminary Results/Development of Sales
M1 Kliniken AG publishes preliminary figures for fiscal year 2019: Net income increases by almost 50 %

15.04.2020 / 09:00
The issuer is solely responsible for the content of this announcement.


M1 Kliniken AG publishes preliminary figures for fiscal year 2019: Net income increases by almost 50 %

- Group sales rose by 18 % to Euro 77.2 million

- Consolidated net income for the year increases by 47 % to Euro 9.7 million

- Proposal for the appropriation of profits: Balance sheet profit to be carried forward to secure the financing of growth

- Outlook 2020: Continuation of the growth path. Temporary burden of closure of clinics and practices - rapid capacity utilization expected after reopening


Berlin, 15.04.2020 - M1 Kliniken AG (ISIN: DE000A0STSQ8) publishes preliminary figures for the financial year 2019. In the past financial year, the M1 Group further strengthened its market leadership in Germany in the field of beauty medicine and accelerated its international expansion.

The M1 Group was able to increase consolidated group sales by 18% to Euro 77.2 million (previous year: Euro 65.2 million) in fiscal year 2019. Sales in the core segment "Beauty" rose by almost 35% compared to the previous year, retail sales increased by almost 5%.

Despite the start-up costs for the establishment of new locations, training and further education of its more than 90 doctors at the 'M1 Akademie', the operating profit (EBIT) increased again in 2019 and grew slightly disproportionate to Euro 7.9 million (+22% compared to the previous year). Earnings before taxes rose from Euro 8.1 million to Euro 12.7 million. This includes a strong financial result of Euro 4.8 million from the investment of existing liquidity. Consolidated net income for the year increased by 47 % to Euro 9.7 million (previous year: Euro 6.6 million). M1 has thus improved earnings per share to Euro 0.56 (previous year: Euro 0.38).

The equity ratio remains at a very high level of just under 74% - but below the previous year's figure due to the effects of the first-time application of IFRS 16 regulations. The operating cash flow amounted to Euro -5.4 million due to the strong growth of investments.

At the end of the year, M1 decided to focus the scope of the treatment areas. This led to an acceleration of the roll-out of laser equipment in additional beauty centres, while the range of dental treatments is to be focused on selected locations.

According to current planning, the Management Board expects to continue the company's growth path in 2020, although a precise forecast cannot be made due to the unclear effects of the Covid 19 pandemic. The main focus of M1's business activities in the current year will be the opening of new specialist centres in Germany and abroad. Management continues to plan to operate a total of 100 specialist centres for aesthetic medicine by the end of 2023 (status at the end of 2019: 36).

Due to the drastic developments since mid-March of the current financial year, the Management Board will propose to the Annual General Meeting that the net profit shall be carried forward. This is intended to secure the company's liquidity to finance further growth.

The 2019 annual report of M1 Kliniken AG is expected to be published on 20 May 2020.

About M1 Kliniken AG
M1 Kliniken AG is the leading provider of beauty medicine health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality. Under the brands M1 Med Beauty, M1 Laser and M1 Dental, beauty medical treatments are currently offered at more than 35 locations. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. Since the end of 2018, M1 has been pushing ahead with its international expansion and is currently active in Austria, Switzerland, the Netherlands, UK and Australia. The Group is now also growing in other European countries. It markets high-quality products to private customers, doctors, pharmacies and wholesalers under the M1 Select and M1 Aesthetics brands. www.m1-kliniken.de

Contact:
M1 Kliniken AG
Grünauer Straße 5; D-12557 Berlin
Phone: +49 (0)30 347 47 44 14
E-mail: [email protected]
Web: www.m1-kliniken.de
 



15.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Germany
Phone: +49 (0)30 347 47 44 14
Fax: +49 (0)30 347 47 44 17
E-mail: [email protected]
Internet: https://www.m1-kliniken.de
ISIN: DE000A0STSQ8
WKN: A0STSQ
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Stuttgart, Tradegate Exchange
EQS News ID: 1021083

 
End of News DGAP News Service

1021083  15.04.2020 

fncls.ssp?fn=show_t_gif&application_id=1021083&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 47,19 65,21 77,27 159,59 314,61 285,29 302,00
EBITDA1,2 6,18 7,17 11,33 8,89 17,82 15,41 19,85
EBITDA-Marge3 13,10 11,00 14,66 5,57 5,66 5,40
EBIT1,4 5,71 6,46 7,93 4,41 12,13 9,35 14,40
EBIT-Marge5 12,10 9,91 10,26 2,76 3,86 3,28 4,77
Jahresüberschuss1 5,78 6,61 9,73 7,43 10,88 7,07 9,50
Netto-Marge6 12,25 10,14 12,59 4,66 3,46 2,48 3,15
Cashflow1,7 2,09 2,86 -5,37 9,54 15,68 20,77 0,00
Ergebnis je Aktie8 0,38 0,39 0,56 0,37 0,45 0,22 0,39
Dividende8 0,30 0,30 0,00 0,00 0,00 0,00 0,30
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2022 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: wetreu NTRG

INVESTOR-INFORMATIONEN
©boersengefluester.de
M1 Kliniken
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0STSQ 13,450 Kaufen 264,20
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
19,49 28,12 0,69 35,49
KBV KCV KUV EV/EBITDA
2,70 12,72 0,93 16,42
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 17.07.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
06.06.2024 03.09.2024 16.11.2023 23.05.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,32% 31,91% 20,09% 68,97%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu M1 Kliniken AG  ISIN: DE000A0STSQ8 können Sie bei EQS abrufen


Gesundheit , A0STSQ , M12 , XETR:M12